Home
Live Updates
HI-Bio Announces Positive Results From Phase 2 Study Of Felzartamab For Late Antibody-Mediated Rejection In Kidney Transplant Recipients : comparemela.com
HI-Bio Announces Positive Results From Phase 2 Study Of Felzartamab For Late Antibody-Mediated Rejection In Kidney Transplant Recipients
82% (n=9/11) of patients on felzartamab experienced resolution of antibody-mediated rejection per Banff criteria on biopsy at 24 weeks versus 20% (n
Related Keywords
Stockholm ,
Sweden ,
United States ,
Macau ,
China ,
Hong Kong ,
Vienna ,
Wien ,
Austria ,
Taiwan ,
Georg Bo ,
Uptal Patel ,
Katharina Mayer ,
United Network For Organ Sharing ,
Human Immunology Biosciences Inc ,
University Of Vienna ,
Division Of Nephrology ,
European Renal Association ,
University Vienna ,
Linkedin ,
New England Journal ,
Immunology Biosciences ,
Banff Classification ,
United Network ,
Organ Sharing ,
Chief Medical Officer ,
Medical University ,
Antibody Mediated Rejection ,
Kidney Transplant Recipients ,
Monograph Capital ,
Alpha Wave Global ,
Arkin Bio Capital ,
Jeito Capital ,
Viking Global ,
Kidney Transplant ,
Low Levels ,
Low Positiveb Flow Crossmatch ,
Highly Sensitized Transplant Candidates ,
comparemela.com © 2020. All Rights Reserved.